- Home
- EDRY vs TENX Comparison
EDRY vs TENX Comparison
Compare EDRY & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDRY | TENX |
|---|---|---|
| Founded | 2018 | 1967 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.3M | 56.2M |
| IPO Year | 2018 | 2001 |
Fundamental Metrics
Financial Performance| Metric | EDRY | TENX |
|---|---|---|
| Price | $18.59 | $14.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 30.3K | ★ 343.5K |
| Earning Date | 02-19-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.85 | N/A |
| Revenue Next Year | $10.51 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.64 | $4.64 |
| 52 Week High | $23.98 | $18.38 |
Technical Indicators
Market Signals| Indicator | EDRY | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 52.65 | 61.77 |
| Support Level | $11.73 | $5.99 |
| Resistance Level | $23.98 | $18.38 |
| Average True Range (ATR) | 1.63 | 1.20 |
| MACD | -0.39 | 0.37 |
| Stochastic Oscillator | 31.92 | 78.18 |
Price Performance
Historical ComparisonAbout EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.